Affect Therapeutics' $16 million Series A funding round was led by ARTIS Ventures and included participation from AlleyCorp, CityLight, LifeArc Ventures, Samsung Next and What If Ventures. In total, Affect Therapeutics has raised about $26 million, said Kristin Muhlner, co-founder and CEO of the company.
Culturally competent behavioral health provider ReKlame Health is rolling out an in-home program for addiction medicine care in New York City. For patients diagnosed with alcohol use disorder, a registered nurse will come to their home on a monthly basis to administer Naltrexone LAI, a medicine that helps stop cravings for opioids and alcohol.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
As a nation, let's face our alcohol dependency head-on and have an honest discussion about the growing consumption trends.
Magellan Healthcare, a managed health company, will offer some California members access to Ria Health's at-home alcohol use disorder treatment program.
The company got a breakthrough device designation for its app-based program for alcohol use disorder, reset-A. Pear currently has FDA-cleared digital therapeutics to address opioid use and substance use disorders.
Through the partnership, Highmark members will gain access to a personalized digital program that aims to reduce harmful drinking. The program includes virtual visits, medication-assisted treatment and coaching support.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
This rapid transition to online care may seem abrupt, but the evidence base for the change is there. Telemedicine is here to stay and is supported by data both on clinical outcomes and return on investment.